Abstract
Feprazone, a non-steroidal anti-inflammatory drug, was compared with indomethacin in a double-blind cross-over trial in 24 patients with ankylosing spondylitis, over eight weeks. Both regimes caused significant reduction in pain. There were fewer side-effects and more patient preferences with feprazone but these differences did not reach statistical significance.
Publication types
-
Clinical Trial
-
Comparative Study
-
Controlled Clinical Trial
MeSH terms
-
Adult
-
Analgesics / therapeutic use
-
Anti-Inflammatory Agents / adverse effects
-
Anti-Inflammatory Agents / therapeutic use*
-
Clinical Trials as Topic
-
Double-Blind Method
-
Female
-
Feprazone / adverse effects
-
Feprazone / therapeutic use*
-
Humans
-
Indomethacin / adverse effects
-
Indomethacin / therapeutic use
-
Male
-
Middle Aged
-
Phenylbutazone / analogs & derivatives*
-
Spondylitis, Ankylosing / drug therapy*
Substances
-
Analgesics
-
Anti-Inflammatory Agents
-
Feprazone
-
Phenylbutazone
-
Indomethacin